127462-76-4

Upstream product

• 37677-17-1 1-bromomethylcyclohexene 
• 57234-28-3 1-methoxy-3-(methoxymethoxy)benzene 
• 18448-47-0 methyl cyclohex-1-ene-1-carboxylate 
• 150-19-6 O-methylresorcine 
• 1617-22-7 cyclohex-1-enecarboxylic acid ethyl ester 
• 108-94-1 cyclohexanone 
• 107-30-2 chloromethyl methyl ether 
• 108-95-2 phenol 

Downstream Products

• 127462-80-0 3-(1'-cyclohexenyl)methyl-4-methoxy-2-(methoxymethoxy)benzyl alcohol 
• 127462-77-5 3-(1'-CYCLOHEXENYL)-METHYL-2-HYDROXY-4-METHOXYBENZOIC ACID 
• 127462-79-7 3-(1'-CYCLOHEXENYL)METHYL-2-HYDROXY-4-METHOXYBENZALDEHYDE 
• 127462-82-2 N-methyl-3-(1'-cyclohexenyl)methyl-2-hydroxy-4-methoxybenzamide 
• 127462-78-6 3-(1'-cyclohexeneylmethyl)-4-methoxy-2-(methoxymethoxy)benzaldehyde 
• 127462-83-3 N-methyl-8-(1'-cyclohexenyl)methyl-7-methoxy-1,3-benzoxazine-2,4-dione 

Relevant academic research and scientific papers

Compounds that inhibit complement and/or suppress immune activity

The present invention is directed to compounds which suppress immune responses and/or selectively inhibit complement. These compounds contain an aromatic ring and are substituted dihydrobenzofurans, spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates. The compounds of the present invention, and the pharmaceutically acceptable salts thereof, interrupt the proteolytic processing of C5 to bioactive components, exhibit immunosuppressive activities, and have therapeutic utility in the amelioration of disease and disorders mediated by complement and/or immune activity.

Compounds which inhibit complement and/or suppress immune activity

The present invention is directed to compounds which suppress immune responses and/or selectively inhibit complement. These compounds contain an aromatic ring and are substituted dihydrobenzofurans, spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates. The compounds of the present invention, and the phamaceutically acceptable salts thereof, interrupt the proteolytic processing of C5 to bioactive components, exhibit immunosuppressive activites, and have therapeutic utility in the amelioration of disease and disorders mediated by complement and/or immune activity.

Compounds which inhibit complement and/or suppress immune activity

The present invention is directed to compounds which suppress immune responses and/or selectively inhibit complement. These compounds contain an aromatic ring and are substituted dihydrobenzofurans, spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates. The compounds of the present invention, and the pharmaceutically acceptable salts thereof, interrupt the proteolytic processing of C5 to bioactive components, exhibit immunosuppressive activities, and have therapeutic utility in the amelioration of disease and disorders mediated by complement and/or immune activity.

Synthesis of 4,7-Disubstituted Spirobenzofuran-2(3H)-cyclohexanes

A general synthetic strategy was designed for the preparation of 7-substituted-4-methoxy- and 4-hydroxyspiro 5 and 6 (Figure 1) using successive, regioselective heteroatom-facilitated aromatic lithiation reactions and subsequent reaction with various electrophiles.